Thoracic and Renal Oncology
Everimmune is active in non-small cell lung cancer and renal cell carcinoma, with a focus on advanced solid tumours treated in combination with immunotherapy. Its clinical research includes patients with metastatic disease and tumour settings linked to PD-L1-based chemo-immunotherapy.
- Non-small cell lung cancer
- Renal cell carcinoma
- Advanced solid tumours
- Metastatic cancer
The sponsor’s oncology interest is centred on treatment combinations used in difficult-to-treat disease, particularly in patients whose tumour biology is linked to Akkermansia deficiency.
Immuno-Oncology
Research activity includes PD-L1-based immunotherapy and chemo-immunotherapy approaches, reflecting a strong interest in immune-directed cancer treatment. The trial landscape also involves combination strategies for patients with advanced malignancies.
- PD-L1-based immunotherapy
- Chemo-immunotherapy
- Combination cancer therapy
- Immune-targeted oncology
These studies place emphasis on therapeutic settings where immune modulation is integrated with established cancer regimens.
Microbiome-Linked Cancer Care
Everimmune’s research also extends to the relationship between gut microbiome status and cancer treatment, with specific attention to Akkermansia-deficient patients. This area connects microbial profiling with oncology care in both NSCLC and RCC.
- Gut microbiome
- Akkermansia
- Microbiome deficiency
- Biology-guided oncology
The sponsor’s studies explore how microbiome-related characteristics intersect with immune-based treatment in solid tumours.
Solid Tumour Therapeutics
The clinical programme is directed toward solid tumour treatment, with a focus on patients whose disease is advanced and who may benefit from adjunctive immunological strategies. The research setting includes oncology care across multiple collaborating sites in France and Europe.
- Solid tumour oncology
- Advanced cancer management
- Multicentre oncology research
- European clinical research
Its current work is concentrated in a small but active clinical network supporting cancer-focused therapeutic development.
